2026 #NLASessions Expert Theater Lineup

 

Expert Theaters are industry supported, non CME educational sessions held during designated breaks in the official meeting schedule. These focused programs feature thought leaders and clinical experts who dive into timely topics in lipid management, cardiovascular risk reduction, and emerging therapies.

Attendance is open to all registered meeting participants and food and beverages (provided by the NLA) are offered at every Expert Theater.

 

 Thursday, June 11 | 3:00-3:50pm CT

  Break food and beverage provided by the NLA

Advancing LDL-C Management in Pediatric and Adult HoFH

Sheraton Ballroom 3 | Sponsored by Chiesi Global Rare Disease


Speakers

Archna Bajaj, MD, FNLA
Assistant Professor of Clinical Medicine
Physician, Corporal Michael J. Crescenz Philadelphia VA Medical Center
Director, Clinical Trials, Penn Medicine Center for Preventive Cardiology and Lipid Management
University of Pennsylvania
Philadelphia, PA
 

Michael Minicucci
Patient Ambassador

Redefining Risk: Leveraging CCTA and Plaque Analysis for Personalized Cardiovascular Prevention

Sheraton Ballroom 2 | Sponsored by Heartflow

This Expert Theater will cover the use of CCTA and Heartflow Plaque Analysis for precise cardiovascular risk stratification, focusing on identifying patient populations, providing practical insights into clinical integration, and exploring the future of plaque-focused prevention strategies.


Speakers

Nihar R. Desai, MD, MPH, FNLA
Associate Professor of Medicine
Yale School of Medicine
Vice Chief, Section of Cardiovascular Medicine
Investigator, Center for Outcomes Research and Evaluation
New Haven, CT

Sarah Rinehart, MD, FACC, FSCC
Medical Director Cardiac Imaging Center
CV CT, Lipid/Prevention Clinic
Charleston Area Medical Center
Charleston, WV

 

 Friday, June 12 | 12:25-1:15pm CT

  Lunch provided by the NLA

TRYNGOLZA: proven results and real-patient experiences

Sheraton Ballroom 2 | Sponsored by Ionis Pharmaceuticals

Please join Dr. Eliot Brinton at NLA's 2026 Scientific Sessions for a presentation on TRYNGOLZA®, the first FDA-approved therapy for adults with familial chylomicronemia syndrome (FCS) as an adjunct to diet.


Speaker

Eliot Brinton, MD, FNLA
President and Director
Utah Lipid Center
Adjunct Faculty

University of Utah School of Medicine

Elevated Lp(a) and Residual Cardiovascular Risk:
Identifying High-Risk Patients for Advanced Intervention with Lipoprotein Apheresis
Sheraton Ballroom 3 | Sponsored by Kaneka - LIPOSORBER

Moderator

Francoise Marvel, MD
Cardiologist
Director & Assistant Professor
Johns Hopkins School of Medicine

Baltimore, MD

Speaker

David Saxon, MD
Endocrinologist
Medical Director, Lipid Apheresis Unit
University of Colorado School of Medicine
Aurora, CO
 
 

 Saturday, June 13 | 8:00-8:50am CT

  Breakfast provided by the NLA

Redemplo® (plozasiran): A Treatment to Lower Triglycerides in Adults With Familial Chylomicronemia Syndrome (FCS)

Sheraton Ballroom 2 | Sponsored by Arrowhead Pharmaceuticals, Inc.

 

Speaker

James A. Underberg, MD, MS, MNLA
Clinical Assistant Professor
Department of Medicine at NYU Grossman School of Medicine
Investigator, Center For Outcomes Research and Evaluation

Uncover HoFH, an ultra-rare lipid disorder, and Explore EVKEEZA (evinacumab-dgnb) as a treatment option

Sheraton Ballroom 3 | Sponsored by Regeneron

This Expert Theater will cover the use of CCTA and Heartflow Plaque Analysis for precise cardiovascular risk stratification, focusing on identifying patient populations, providing practical insights into clinical integration, and exploring the future of plaque-focused prevention strategies.

 

Speaker

Alan S. Brown, MD, MPH, MNLA

 

 Saturday, June 13 | 12:35-1:25pm CT

  Lunch provided by the NLA

Identification and Stratification of Patients at High CV Risk without a Prior MI or Stroke: Insights from Real-World Evidence and the VESALIUS-CV Trial

Sheraton Ballroom 3 | Sponsored by Amgen

Join a cardiovascular expert as they explore how to reduce the risk of MACE in patients at high CV risk without a previous MI or stroke. Featuring data from the VESALIUS-CV outcomes trial alongside real-world evidence, this session highlights the urgent need for risk identification and treatment.

Please join our presentation on the unmet need, urgent risks associated with sHTG, and expert recommendations for managing patients with triglycerides ≥500 mg/dL.


Speaker

Nihar R. Desai, MD, MPH, FNLA
Associate Professor, Yale School of Medicine
Vice Chief, Section of Cardiovascular Medicine
Investigator, Center For Outcomes Research and Evaluation

 

Severe Hypertriglyceridemia (sHTG) | An Underrecognized, Life-Threatening Disease

Sheraton Ballroom 2 | Sponsored by Ionis Pharmaceuticals

Please join our presentation on the unmet need, urgent risks associated with sHTG, and expert recommendations for managing patients with triglycerides ≥500 mg/dL.


Speaker

P. Barton Duell, MD, MNLA
Professor of Medicine
Division of Cardiovascular Medicine, School of Medicine
Oregon Health & Science University